Long-term adverse effect of liver stiffness on Glycaemic Control in Type 2 Diabetic patients with nonalcoholic Fatty liver disease: A pilot study
Long-term adverse effect of liver stiffness on Glycaemic Control in Type 2 Diabetic patients with nonalcoholic Fatty liver disease: A pilot study
Currently, there are limited data regarding the long-term effect of liver stiffness on glycaemic control in patients with type 2 diabetes mellitus (T2DM) and nonalcoholic fatty liver disease (NAFLD). We prospectively followed an outpatient sample of 61 consecutive postmenopausal women with T2DM and NAFLD who had baseline data on liver ultrasonography and Fibroscan®-assessed liver stiffness measurement (LSM) in 2017 and who underwent follow-up in 2022. Haemoglobin A1c (HbA1c) was measured both at baseline and follow-up. At baseline, 52 patients had NAFLD (hepatic steatosis) alone, and 9 had NAFLD with coexisting clinically significant fibrosis (defined as LSM ≥ 7 kPa on Fibroscan®). At follow-up, 16 patients had a worsening of glycaemic control (arbitrarily defined as HbA1c increase ≥ 0.5% from baseline). The prevalence of NAFLD and coexisting clinically significant fibrosis at baseline was at least three times greater among patients who developed worse glycaemic control at follow-up, compared with those who did not (31.3% vs. 8.9%; p = 0.030). In logistic regression analysis, the presence of NAFLD and clinically significant fibrosis was associated with an approximately 4.5-fold increased likelihood of developing worse glycaemic control at follow-up (odds ratio 4.66, 95% confidence interval 1.07–20.3; p = 0.041), even after adjustment for baseline confounding factors, such as age, body mass index, haemoglobin A1c (or HOMA-estimated insulin resistance) and use of some glucose-lowering agents that may positively affect NAFLD and liver fibrosis. In conclusion, our results suggest that the presence of Fibroscan®-assessed significant fibrosis was associated with a higher risk of developing worse glycaemic control in postmenopausal women with T2DM and NAFLD.
12481
Mantovani, Alessandro
140b374f-bea1-4076-8650-989d38d8b8e0
Taverna, Antonio
3f2e91bb-d5cd-40a9-b48d-0bc3926a17c0
Cappelli, Davide
a6799027-efe8-4562-9e89-144fc42a144e
Beatrice, Giorgia
6e71c7aa-e5c3-4232-805d-97197b170575
Csermely, Alessandro
f790ec1b-608f-4a1f-a6df-54bf59e04653
Sani, Elena
b1516819-68e6-45b8-8c60-ada85d0cb766
Byrne, Christopher
1370b997-cead-4229-83a7-53301ed2a43c
Targher, Giovanni
8a57cd78-c539-4b77-9ba8-1d7fff1c957f
18 October 2022
Mantovani, Alessandro
140b374f-bea1-4076-8650-989d38d8b8e0
Taverna, Antonio
3f2e91bb-d5cd-40a9-b48d-0bc3926a17c0
Cappelli, Davide
a6799027-efe8-4562-9e89-144fc42a144e
Beatrice, Giorgia
6e71c7aa-e5c3-4232-805d-97197b170575
Csermely, Alessandro
f790ec1b-608f-4a1f-a6df-54bf59e04653
Sani, Elena
b1516819-68e6-45b8-8c60-ada85d0cb766
Byrne, Christopher
1370b997-cead-4229-83a7-53301ed2a43c
Targher, Giovanni
8a57cd78-c539-4b77-9ba8-1d7fff1c957f
Mantovani, Alessandro, Taverna, Antonio, Cappelli, Davide, Beatrice, Giorgia, Csermely, Alessandro, Sani, Elena, Byrne, Christopher and Targher, Giovanni
(2022)
Long-term adverse effect of liver stiffness on Glycaemic Control in Type 2 Diabetic patients with nonalcoholic Fatty liver disease: A pilot study.
International Journal of Molecular Sciences, 23 (20), .
Abstract
Currently, there are limited data regarding the long-term effect of liver stiffness on glycaemic control in patients with type 2 diabetes mellitus (T2DM) and nonalcoholic fatty liver disease (NAFLD). We prospectively followed an outpatient sample of 61 consecutive postmenopausal women with T2DM and NAFLD who had baseline data on liver ultrasonography and Fibroscan®-assessed liver stiffness measurement (LSM) in 2017 and who underwent follow-up in 2022. Haemoglobin A1c (HbA1c) was measured both at baseline and follow-up. At baseline, 52 patients had NAFLD (hepatic steatosis) alone, and 9 had NAFLD with coexisting clinically significant fibrosis (defined as LSM ≥ 7 kPa on Fibroscan®). At follow-up, 16 patients had a worsening of glycaemic control (arbitrarily defined as HbA1c increase ≥ 0.5% from baseline). The prevalence of NAFLD and coexisting clinically significant fibrosis at baseline was at least three times greater among patients who developed worse glycaemic control at follow-up, compared with those who did not (31.3% vs. 8.9%; p = 0.030). In logistic regression analysis, the presence of NAFLD and clinically significant fibrosis was associated with an approximately 4.5-fold increased likelihood of developing worse glycaemic control at follow-up (odds ratio 4.66, 95% confidence interval 1.07–20.3; p = 0.041), even after adjustment for baseline confounding factors, such as age, body mass index, haemoglobin A1c (or HOMA-estimated insulin resistance) and use of some glucose-lowering agents that may positively affect NAFLD and liver fibrosis. In conclusion, our results suggest that the presence of Fibroscan®-assessed significant fibrosis was associated with a higher risk of developing worse glycaemic control in postmenopausal women with T2DM and NAFLD.
Text
ijms-1922208_accepted open access
- Accepted Manuscript
Text
Supplementary materials_accepted
- Accepted Manuscript
Restricted to Repository staff only
Request a copy
Text
ijms-23-12481 (1)
- Version of Record
Text
ijms-23-12481
- Version of Record
More information
Accepted/In Press date: 11 October 2022
Published date: 18 October 2022
Identifiers
Local EPrints ID: 471467
URI: http://eprints.soton.ac.uk/id/eprint/471467
ISSN: 1422-0067
PURE UUID: 651de78a-e883-4db2-952f-6f15f10e1516
Catalogue record
Date deposited: 08 Nov 2022 18:54
Last modified: 17 Mar 2024 02:49
Export record
Contributors
Author:
Alessandro Mantovani
Author:
Antonio Taverna
Author:
Davide Cappelli
Author:
Giorgia Beatrice
Author:
Alessandro Csermely
Author:
Elena Sani
Author:
Giovanni Targher
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics
